EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The Pharmacokinetics and Relative Bioavailability of a Mini‐Tablet of Mercaptopurine, a Novel Formulation for Use in Children with Acute Lymphoblastic Leukemia

Zhi Chen, Yuan-Yuan Zheng, Qing-Liang Liu, Pan-Pan Ye, Xin-Mei Yang, Lin-Lin Song, Ke-Guang Chen, Fu-Rong Zhao, Jin-Yi Shi, Ye-Hui Zhang, Hai-Yan Zhou, John van den Anker und 6 weitere

The Journal of Clinical Pharmacology · 2026-04 · 66 (4)

DOI: 10.1002/jcph.70178 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 03.04.2026. Verfasst von Zhi Chen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Me…. Hauptthemen laut MEDLINE: Mercaptopurine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antimetabolites, Antineoplastic. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Taishan Scholar Program of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel 5 mg mini‐tablet formulation of mercaptopurine (6‐MP) was developed to provide flexible and accurate doses to treat children with acute lymphoblastic leukemia. We conducted two open‐label, randomized, single‐dose, four‐period, two‐sequence, full‐replicate, crossover trials to characterize the pharmacokinetics and relative bioavailability of the novel 6‐MP mini‐tablet (N) compared to the reference 6‐MP tablet (R) under both fasted and fed conditions. The 6‐MP plasma concentrations were measured using ultra performance liquid chromatography ‐ tandem mass spectrometry (UPLC‐MS/MS). The C max , AUC 0–t , and AUC 0–inf were used to evaluate the relative bioavailability. The results showed that the 6‐MP mini‐tablet was bioequivalent to the reference formulation under fasting condition. Under the fasted condition, the geometric least‐squares mean ratios (GLSMR) (90% CI) of C max , AUC 0–t , and AUC 0–inf of N over R were 91.71% (81.31%–103.44%), 97.53% (92.57%–102.76%), and 97.91% (93.17%–102.90%), respectively. The mean CL/F (238.4 vs 219.3 L/h), the mean V d /F (523.4 vs 451.8 L), the median T max (1.50 vs 1.25 h), and the mean t 1/2 (1.55 vs 1.44 h) of N and R showed similarity. Under fed condition, the GLSMR (90% CI) of C max , AUC 0–t , and AUC 0–inf of N over R were 68.16% (59.62%–77.93%), 86.22% (81.37%–91.37%), and 86.59% (81.88%–91.57%), respectively. Furthermore, a high‐fat diet increased both CL/F and V d /F of 6‐MP and decreased exposure of 6‐MP, with all changes exceeding two‐fold. Both products exhibited a favorable safety profile without any SAE being observed. These results supported the marketing of 6‐MP mini‐tablets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MercaptopurinePrecursor Cell Lymphoblastic Leukemia-LymphomaAntimetabolites, AntineoplasticHumansBiological AvailabilityMaleCross-Over StudiesTabletsFemaleChildArea Under CurveFastingTherapeutic EquivalencyTandem Mass SpectrometryChild, PreschoolAdolescent

Stichwörter der Autor:innen

food effectmercaptopurinemini‐tabletpharmacokineticsrelative bioavailability

Substanzen

MercaptopurineTabletsAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Devel…
  • China Resources Double-Crane Pharmaceutical Co., Ltd., Beijing, China.

ORCID-Profile: Wei Zhao

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program of China
  • Taishan Scholar Program of Shandong Province
  • National Science Foundation for Young Scientists of China
  • Natural Science Foundation of Shandong Province
  • China Resources Double-Crane Pharmaceutical Co., Ltd
  • National Basic Research Program of China

Zitieren

APA

Chen, Z., Zheng, Y. Y., Liu, Q. L., Ye, P. P., Yang, X. M., Song, L. L., Chen, K. G., Zhao, F. R., Shi, J. Y., Zhang, Y. H., Zhou, H. Y., van den Anker, J., Yang, Y., Zhao, Q., Li, Q., Lu, W. C., Zhou, Y., & Zhao, W. (2026). The Pharmacokinetics and Relative Bioavailability of a Mini‐Tablet of Mercaptopurine, a Novel Formulation for Use in Children with Acute Lymphoblastic Leukemia. The Journal of Clinical Pharmacology, 66(4). https://doi.org/10.1002/jcph.70178

Vancouver

Chen Z, Zheng YY, Liu QL, Ye PP, Yang XM, Song LL, et al. The Pharmacokinetics and Relative Bioavailability of a Mini‐Tablet of Mercaptopurine, a Novel Formulation for Use in Children with Acute Lymphoblastic Leukemia. The Journal of Clinical Pharmacology. 2026;66(4). doi:10.1002/jcph.70178

BibTeX
@article{Chen2026,
  author = {Chen, Zhi and Zheng, Yuan-Yuan and Liu, Qing-Liang and Ye, Pan-Pan and Yang, Xin-Mei and Song, Lin-Lin and Chen, Ke-Guang and Zhao, Fu-Rong and Shi, Jin-Yi and Zhang, Ye-Hui and Zhou, Hai-Yan and van den Anker, John and Yang, Yan and Zhao, Qian and Li, Qian and Lu, Wen-Chao and Zhou, Yue and Zhao, Wei},
  title = {The Pharmacokinetics and Relative Bioavailability of a Mini‐Tablet of Mercaptopurine, a Novel Formulation for Use in Children with Acute Lymphoblastic Leukemia},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {4},
  doi = {10.1002/jcph.70178}
}
Kostenlos starten →